BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Shameem R, Hamid MS, Xu KY, Wu S. Comparative analysis of the effectiveness of abiraterone before and after docetaxel in patients with metastatic castration-resistant prostate cancer. World J Clin Oncol 2015; 6(4): 64-72 [PMID: 26266103 DOI: 10.5306/wjco.v6.i4.64]
URL: https://www.wjgnet.com/2218-4333/full/v6/i4/64.htm
Number Citing Articles
Haofeng Zheng, Jialiang Chen, Wenhan Qiu, Sijie Lin, Yanxiong Chen, Guancan Liang, Youqiang Fang. Safety and Efficacy of First-Line Treatments for Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer: A Systematic Review and Indirect ComparisonBioMed Research International 2017; 2017: 1 doi: 10.1155/2017/3941217
M. Koninckx, J. L. Marco, I. Pérez, M. T. Faus, V. Alcolea, F. Gómez. Effectiveness, safety and cost of abiraterone acetate in patients with metastatic castration-resistant prostate cancer: a real-world data analysisClinical and Translational Oncology 2019; 21(3): 314 doi: 10.1007/s12094-018-1921-5
Chengkuan Cai, Jingyuan Tang, Baixin Shen, Liucheng Ding, Yunpeng Shao, Zhengsen Chen, Yinchao Ma, Haoliang Xue, Zhongqing Wei. Preclinical trial of the multi-targeted lenvatinib in combination with cellular immunotherapy for treatment of renal cell carcinomaExperimental and Therapeutic Medicine 2017; 14(4): 3221 doi: 10.3892/etm.2017.4858
Seung-hwan Jeong, Sang Eun Yeon, Su Youn Kim, Tae Gyun Kwon, Seong Soo Jeon, Young Deuk Choi, Dongdeuk Kwon, Byung Ha Chung, Sung-Hoo Hong, Byung Hoon Kim, Hyo Jin Lee, Sang Joon Shin, Woo Suk Choi, Sung Woo Park, Taek Won Kang, Seok Joong Yun, Jin Seon Cho, See Min Choi, Na-Ri Lee, Cheol Kwak. A prospective, multicenter study on the clinical effectiveness of abiraterone in metastatic castration-resistant prostate cancer in Korea: Pre- vs. post-chemotherapyInvestigative and Clinical Urology 2023; 64(5): 466 doi: 10.4111/icu.20230128
Kapil Dev Mehta. Abiraterone: A Review of its Pharmacokinetic, Pharmacodynamic Profile and Clinical EfficacyUrology & Nephrology Open Access Journal 2016; 3(3) doi: 10.15406/unoaj.2016.03.00079
Sabin Goktas Aydin, Yasin Kutlu, Harun Muglu, Ahmet Aydin, Ozgur Acikgoz, Jamshid Hamdard, Ebru Karci, Ahmet Bilici, Omer Fatih Olmez, Ozcan Yildiz. Predictive significance of inflammatory markers and mGPS in metastatic castration-resistant prostate cancer treated with abiraterone or enzalutamideCancer Chemotherapy and Pharmacology 2024; 93(1): 71 doi: 10.1007/s00280-023-04592-x
Rahma Said, Javier Hernández‐Losa, Amine Derouiche, Teresa Moline, Rosa Somoza Lopez de Haro, Skander Zouari, Ahlem Blel, Soumaya Rammeh, Slah Ouerhani. Correlation between E‐cadherin/β‐catenin, Vimentin expression, clinicopathologic features and drug resistance prediction in naïve prostate cancer: A molecular and clinical studygenesis 2024; 62(1) doi: 10.1002/dvg.23543
Bin Zhang, Feng Tao, Hao Zhang. Metastasis-associated protein 2 promotes the metastasis of non-small cell lung carcinoma by regulating the ERK/AKT and VEGF signaling pathwaysMolecular Medicine Reports 2018;  doi: 10.3892/mmr.2018.8535
George Liamis, Theodosios D. Filippatos, Moses S. Elisaf. Electrolyte disorders associated with the use of anticancer drugsEuropean Journal of Pharmacology 2016; 777: 78 doi: 10.1016/j.ejphar.2016.02.064